Voya Investment Management LLC Sells 815,679 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Voya Investment Management LLC lowered its position in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 39.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,255,034 shares of the biotechnology company's stock after selling 815,679 shares during the quarter. Voya Investment Management LLC owned 0.18% of OPKO Health worth $1,845,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Cibc World Markets Corp acquired a new stake in OPKO Health during the 4th quarter worth about $45,000. Zacks Investment Management acquired a new position in OPKO Health in the 4th quarter worth approximately $49,000. Ieq Capital LLC purchased a new position in OPKO Health during the 4th quarter worth approximately $52,000. World Investment Advisors LLC acquired a new stake in OPKO Health during the 3rd quarter valued at $61,000. Finally, Catalyst Funds Management Pty Ltd purchased a new stake in shares of OPKO Health in the fourth quarter valued at $91,000. 64.63% of the stock is currently owned by institutional investors.

OPKO Health Stock Down 0.4 %

Shares of OPKO Health stock traded down $0.01 during midday trading on Friday, reaching $1.26. 3,681,847 shares of the company's stock traded hands, compared to its average volume of 3,899,336. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. OPKO Health, Inc. has a 52 week low of $1.19 and a 52 week high of $2.04. The company's 50 day simple moving average is $1.57 and its 200 day simple moving average is $1.56. The company has a market cap of $995.28 million, a price-to-earnings ratio of -6.61 and a beta of 1.42.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.03). OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The company had revenue of $149.90 million for the quarter, compared to analyst estimates of $163.13 million. During the same period in the prior year, the company posted ($0.12) EPS. The business's revenue was down 13.7% on a year-over-year basis. Equities analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Phillip Md Et Al Frost purchased 200,000 shares of the firm's stock in a transaction on Monday, March 17th. The shares were bought at an average cost of $1.74 per share, for a total transaction of $348,000.00. Following the transaction, the chief executive officer now directly owns 213,501,448 shares of the company's stock, valued at approximately $371,492,519.52. This trade represents a 0.09 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have acquired 767,434 shares of company stock valued at $1,238,312. 49.69% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. assumed coverage on OPKO Health in a research note on Friday, April 25th. They set a "neutral" rating on the stock. HC Wainwright reiterated a "buy" rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Monday, April 7th. StockNews.com lowered shares of OPKO Health from a "hold" rating to a "sell" rating in a research note on Monday, May 5th. Finally, Barrington Research reaffirmed an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, OPKO Health presently has a consensus rating of "Hold" and an average target price of $2.75.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.